Cellvizio by Mauna Kea Technologies

05/26/2026

is officially expanding into the United Arab Emirates and Turkey!

We’ve obtained key regulatory clearances for in these two major markets, already securing our first commercial sale in the UAE for the CellTolerance program. With and food intolerances impacting up to 27% of the population in these markets, our precision diagnostics are ready to make a major impact.

Read the full press release: https://hubs.ly/Q04hytGJ0

05/21/2026

Cellvizio by Mauna Kea Technologies has obtained regulatory clearances for in the United Arab Emirates and Turkey. These approvals open doors to two of the world's most compelling markets for precision diagnostics where and food intolerances affect up to 27% of the population on average, and up to 39% of young adults in the UAE.

Building immediately on these clearances, we confirm our first commercial sale of Cellvizio in the UAE, dedicated specifically to the program. The region's thriving premium private healthcare sector and strong patient purchasing power make it uniquely suited to our commercial strategy.

Read the full press release: https://hubs.ly/Q04hwR6d0

05/20/2026

Cellvizio by Mauna Kea Technologies has obtained regulatory clearances for in the United Arab Emirates and Turkey. These approvals open doors to two of the world's most compelling markets for precision diagnostics where and food intolerances affect up to 27% of the population on average, and up to 39% of young adults in the UAE.

Building immediately on these clearances, we confirm our first commercial sale of Cellvizio in the UAE, dedicated specifically to the program. The region's thriving premium private healthcare sector and strong patient purchasing power make it uniquely suited to our commercial strategy.

Read the full press release: https://hubs.la/Q04hnlVn0

05/19/2026

Crohn’s Disease and Ulcerative Colitis are two chronic inflammatory bowel diseases ( ) that affect millions of people around the world. While not showing any outward signs of their condition, many struggle to get the support and understanding that they need.

To learn how can be superior to conventional severity scoring, visit: https://hubs.la/Q04gcT9k0



Crohn's & Colitis Foundation

05/07/2026

The stakes for early detection have never been higher. For clinicians, the challenge isn't just treating the lesion, it’s navigating the long road to Complete Remission of Intestinal Metaplasia (CRIM).

We can't control the rise of the disease alone, but with advanced imaging, we can control how we find and treat it.

How it works: https://hubs.la/Q04fTYHg0

05/07/2026

offers unprecedented cellular-level visualization, empowering physicians to understand and treat patients with greater precision unlike any other platform available today. This groundbreaking technology is transforming the landscape of healthcare.

Discover Cellvizio's transformative impact: https://hubs.la/Q04fQQpq0

05/06/2026

According to published data, pancreatic cysts are simultaneously over-resected and under-detected, making the crux of being wrong enormous in either direction. The latest insights from are clear: outperforms conventional pancreatic cyst fluid analysis (CEA, amylase, cytology, glucose) in differentiating benign from malignant or pre-malignant cysts helping ensure the right patients get surgery, and the right patients avoid it.

Get the full details: https://hubs.la/Q04fJRkn0

A size-based, multimodal diagnostic strategy could close dangerous gaps in pancreatic cyst evaluation by combining tools to better distinguish benign from high-risk lesions, says Dr. Somashekar Krishna.

05/05/2026

New data from highlights a pivotal moment for patients struggling with unexplained gut issues. and SIBO diagnosis is moving away from "one-size-fits-all" and toward precision medicine with CellTolerance leading the way.

CLE ( ) can go beyond the surface giving physicians real-time, cellular-level visualization of the intestinal mucosa that conventional testing often misses. For IBS patients who have spent years searching for answers, the test represents a paradigm shift from diagnosis by exclusion to precision diagnosis.

Read the full science breakdown from DDW 2026 here:

Advances in microbiome science and immune-mediated food intolerance are expanding treatment options for patients with IBS and SIBO who have food-associated symptoms, says Dr. Sean Spencer.

05/04/2026

We are proud to be part of the 4th Annual Pancreatic Cyst Consortium at Digestive Disease Week® (DDW®), organized by Som Krishna, MD, MPH, which had record attendance! This major event brought together leading voices for insightful conversations on advancing pancreatic cyst diagnostic and management strategies, all focused on improving patient outcomes.

Thank you to all involved!

04/29/2026

We’re heading to in Chicago from May 2-5 to showcase the massive clinical momentum behind . With 10 accepted abstracts spanning pancreatic cysts, IBD assessment, gastric disease, and food intolerance, this year marks a major leap forward in real-time patient care.

"DDW 2026 is a pivotal moment for Cellvizio. The scale, methodological rigor, independence, and geographic breadth of the work being presented this year...confirm Cellvizio’s importance in the key clinical and commercial indications we are pursuing." Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies.

Join us as we reinforce the power of real-time in vivo cellular imaging in transforming patient care.

Read the full press release: https://hubs.la/Q04dTtND0

Digestive Disease Week® (DDW®)

04/27/2026

Advancement in early esophageal cancer detection could significantly impact global health outcomes! This study demonstrates how is empowering deep learning models to detect esophageal cancer with incredible accuracy. Our breakthrough technology highlights the potential to transform diagnostics by enabling earlier diagnoses and better outcomes.

Learn more about the study: https://hubs.la/Q04dz2Cg0